Treatment of equine sarcoids: A systematic review.
Authors: Offer Katie S, Dixon Claire E, Sutton David G M
Journal: Equine veterinary journal
Summary
# Treatment of Equine Sarcoids: What the Evidence Actually Shows Sarcoids represent the most prevalent skin tumour in horses, yet clinical decision-making around their treatment has historically relied on experience and anecdotal reports rather than robust evidence. Offer and colleagues conducted a systematic review of interventional studies meeting level 4 evidence or higher, screening five major databases for papers that included histopathological confirmation of at least some lesions and minimum six-month follow-up; only 10 studies met inclusion criteria. Regression rates varied dramatically across treatments, ranging from 28–100% at the individual lesion level and 9–100% across whole horses, with transient local inflammation the most commonly reported side effect. Critically, the authors found insufficient evidence to recommend any single treatment approach over others, highlighting that 60% of included papers failed to confirm diagnosis histopathologically in all cases and significant heterogeneity between studies prevented meaningful quantitative comparison. For practitioners selecting sarcoid treatments—whether cryotherapy, topical agents, surgical excision, or immunological approaches—this review underscores the sobering reality that current clinical practice outpaces published evidence, and substantial investment in well-designed randomised controlled trials is essential before definitive treatment recommendations can be made.
Read the full abstract on PubMed
Practical Takeaways
- •Currently, no single sarcoid treatment can be recommended as superior based on available evidence—treatment selection should consider individual case factors and owner preferences rather than relying on evidence-based guidelines
- •Ensure histopathological confirmation of sarcoid diagnosis before committing to treatment, as diagnostic inconsistency is common in the literature and affects outcome interpretation
- •Prepare clients to expect transient local inflammation as a normal response to most sarcoid treatments; this is not necessarily a sign of treatment failure
Key Findings
- •Sarcoid regression rates ranged from 28% to 100% at individual lesion level and 9% to 100% at whole horse level across included studies
- •Only 60% of included papers confirmed case definition via histopathology in all lesions, indicating inconsistent diagnostic standards
- •Significant heterogeneity between the 10 included studies prevented quantitative synthesis and most papers had critical or concerning risk of bias
- •Transient local inflammation was common following most treatment strategies, with few other adverse events reported